



ASX Announcement

6 February 2019

Suspension Update

Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) advises that it is currently in consultation with the ASX in relation to the application of Chapter 11 (Significant Transactions) of the ASX Listing Rules to the two potential transactions that were previously disclosed in cleansing statements released by the Company on 31 January 2019 and 1 February 2019.

Creso is working to have these discussions concluded shortly, and anticipates trading to recommence on or before Tuesday, 12 February 2019.

---END---

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Corporate Enquiries

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney NSW 2000
E: info@everblucapital.com
T: +61 (02) 8249 0000